Literature DB >> 21795465

Neutralizing activity of saliva against cytomegalovirus.

Frances M Saccoccio1, Mary K Gallagher, Stuart P Adler, Michael A McVoy.   

Abstract

Congenital cytomegalovirus (CMV) disease is the leading cause of permanent disability in neonates in the United States. Neutralizing antibodies in saliva may protect against maternal CMV infection by blocking viral entry into oral epithelial cells, but the antibody response to CMV in the saliva following natural infection is not well characterized. Saliva specimens from naturally infected individuals were tested for CMV-neutralizing activity using epithelial and fibroblast cells. Saliva from seronegative adults had no inherent anti-CMV activity. Neutralizing activity of saliva from naturally infected adults was not detectable using fibroblast cells, and saliva from young children, adolescents, and Towne vaccine recipients did not have activity using either cell type. However, when using epithelial cells, neutralizing activity was present in saliva from 50% of seropositive adults, correlated with serum-neutralizing activity, and was more prevalent in mothers of children in day care than in non-day care-associated adults. Three day care mothers with high salivary neutralizing activities (>1:20) had exceptionally high serum-neutralizing titers (3- to 8-fold higher than typical seropositives) and were immunoblot positive for serum antibodies to the epithelial entry mediator UL130. These results suggest that salivary neutralizing activities are attainable by induction of high serum IgG levels and could be utilized to evaluate candidate cytomegalovirus vaccines.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21795465      PMCID: PMC3165217          DOI: 10.1128/CVI.05128-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  26 in total

1.  Influence of host factors on immunoglobulin G concentration in oral fluid specimens.

Authors:  Timothy C Granade; Susan K Phillips; Wendy Kitson-Piggott; Perry Gomez; Bisram Mahabir; Herbert Oleander; J Richard George; James Baggs; Bharat Parekh
Journal:  Clin Diagn Lab Immunol       Date:  2002-01

2.  Mucosal antibodies to human cytomegalovirus glycoprotein B occur following both natural infection and immunization with human cytomegalovirus vaccines.

Authors:  J B Wang; S P Adler; S Hempfling; R L Burke; A M Duliège; S E Starr; S A Plotkin
Journal:  J Infect Dis       Date:  1996-08       Impact factor: 5.226

3.  Peptides from cytomegalovirus UL130 and UL131 proteins induce high titer antibodies that block viral entry into mucosal epithelial cells.

Authors:  Frances M Saccoccio; Anne L Sauer; Xiaohong Cui; Amy E Armstrong; El-Sayed E Habib; David C Johnson; Brent J Ryckman; Aloysius J Klingelhutz; Stuart P Adler; Michael A McVoy
Journal:  Vaccine       Date:  2011-02-22       Impact factor: 3.641

4.  Human cytomegalovirus UL130 protein promotes endothelial cell infection through a producer cell modification of the virion.

Authors:  Marco Patrone; Massimiliano Secchi; Loretta Fiorina; Mariagrazia Ierardi; Gabriele Milanesi; Andrea Gallina
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

5.  Salivary antibodies to cytomegalovirus (CMV) glycoprotein B accurately predict CMV infections among preschool children.

Authors:  J B Wang; S P Adler
Journal:  J Clin Microbiol       Date:  1996-10       Impact factor: 5.948

6.  Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism.

Authors:  Dai Wang; Thomas Shenk
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

7.  Human cytomegalovirus infection elicits a glycoprotein M (gM)/gN-specific virus-neutralizing antibody response.

Authors:  Masako Shimamura; Michael Mach; William J Britt
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

8.  Vaccine prevention of maternal cytomegalovirus infection.

Authors:  Robert F Pass; Changpin Zhang; Ashley Evans; Tina Simpson; William Andrews; Meei-Li Huang; Lawrence Corey; Janie Hill; Elizabeth Davis; Cynthia Flanigan; Gretchen Cloud
Journal:  N Engl J Med       Date:  2009-03-19       Impact factor: 91.245

9.  Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection.

Authors:  Xiaohong Cui; Benjamin P Meza; Stuart P Adler; Michael A McVoy
Journal:  Vaccine       Date:  2008-08-19       Impact factor: 3.641

10.  Cytomegalovirus infections among African-Americans.

Authors:  Isca R Wilms; Al M Best; Stuart P Adler
Journal:  BMC Infect Dis       Date:  2008-08-01       Impact factor: 3.090

View more
  17 in total

1.  Cytomegalovirus Virions Shed in Urine Have a Reversible Block to Epithelial Cell Entry and Are Highly Resistant to Antibody Neutralization.

Authors:  Xiaohong Cui; Stuart P Adler; Mark R Schleiss; Ravit Arav-Boger; Gail J Demmler Harrison; Michael A McVoy
Journal:  Clin Vaccine Immunol       Date:  2017-06-05

Review 2.  Cytomegalovirus vaccines.

Authors:  Michael A McVoy
Journal:  Clin Infect Dis       Date:  2013-12       Impact factor: 9.079

3.  Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.

Authors:  Mark R Schleiss; Ursula Berka; Elizabeth Watson; Mario Aistleithner; Bettina Kiefmann; Bastien Mangeat; Elizabeth C Swanson; Peter A Gillis; Nelmary Hernandez-Alvarado; Claudia Fernández-Alarcón; Jason C Zabeli; Daniel D Pinschewer; Anders E Lilja; Michael Schwendinger; Farshad Guirakhoo; Thomas P Monath; Klaus K Orlinger
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

4.  A high-affinity native human antibody neutralizes human cytomegalovirus infection of diverse cell types.

Authors:  Lawrence M Kauvar; Keyi Liu; Minha Park; Neal DeChene; Robert Stephenson; Edgar Tenorio; Stote L Ellsworth; Takako Tabata; Matthew Petitt; Mitsuru Tsuge; June Fang-Hoover; Stuart P Adler; Xiaohong Cui; Michael A McVoy; Lenore Pereira
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

5.  Development of a high-throughput assay to measure the neutralization capability of anti-cytomegalovirus antibodies.

Authors:  Thomas J Gardner; Cynthia Bolovan-Fritts; Melissa W Teng; Veronika Redmann; Thomas A Kraus; Rhoda Sperling; Thomas Moran; William Britt; Leor S Weinberger; Domenico Tortorella
Journal:  Clin Vaccine Immunol       Date:  2013-02-06

6.  A cytomegalovirus DNA vaccine induces antibodies that block viral entry into fibroblasts and epithelial cells.

Authors:  Michael A McVoy; Ronzo Lee; Frances M Saccoccio; Jukka Hartikka; Larry R Smith; Rohit Mahajan; Jian Ben Wang; Xiaohong Cui; Stuart P Adler
Journal:  Vaccine       Date:  2015-10-24       Impact factor: 3.641

7.  Human cytomegalovirus vaccine development: Immune responses to look into vaccine strategy.

Authors:  Lin Xia; Ruopeng Su; Zhiqiang An; Tong-Ming Fu; Wenxin Luo
Journal:  Hum Vaccin Immunother       Date:  2017-12-01       Impact factor: 3.452

8.  Antibody inhibition of human cytomegalovirus spread in epithelial cell cultures.

Authors:  Xiaohong Cui; Ronzo Lee; Stuart P Adler; Michael A McVoy
Journal:  J Virol Methods       Date:  2013-05-10       Impact factor: 2.014

9.  Alphaherpesvirinae and Gammaherpesvirinae glycoprotein L and CMV UL130 originate from chemokines.

Authors:  Maja Malkowska; Katarzyna Kokoszynska; Magdalena Dymecka; Leszek Rychlewski; Lucjan S Wyrwicz
Journal:  Virol J       Date:  2013-01-02       Impact factor: 4.099

Review 10.  Viral Manipulation of the Host Epigenome as a Driver of Virus-Induced Oncogenesis.

Authors:  Shimaa Hassan AbdelAziz Soliman; Arturo Orlacchio; Fabio Verginelli
Journal:  Microorganisms       Date:  2021-05-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.